22 search results for: Early Intervention
ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis
Prof. Thomas Bieber explores early intervention and disease modification in atopic dermatitis.
Early Intervention in Pediatric AD: A Critical Window to Alter the Course of AD and Associated Diseases
Dr. Lisa Swanson explores a hypothetical scenario of what might have been achievable for adult patients with atopic dermatitis if advanced systemic therapies had been initiated in early childhood, considering the potential impact on atopic progression, mental health, and bone health and growth outcomes.
Atopic Dermatitis at an Inflection Point: Refining Outcomes Through Timely, Targeted Intervention
At the 2026 EADV Congress, Prof. Tilo Biedermann and Drs. Nicole Chase and Lisa Swanson present a holistic view of atopic dermatitis (AD) management from childhood to adulthood centered around type 2 inflammation. Beginning with the hypothesis that reduced exposure to helminths in increasingly industrialized societies may have diminished natural immunomodulatory mechanisms, they explore how dysregulated type 2 inflammation can manifest as AD and extend beyond the skin. The discussion then focuses on adults with uncontrolled AD, highlighting the multidimensional, cumulative burden of disease across the lifespan—and how targeted systemic therapy may help achieve sustained disease control. Finally, the faculty explore pediatric AD as a critical window for early intervention, with the potential to alter disease progression and prevent comorbidities.
Early Intervention May Have the Potential to Alter the Trajectory of Atopic Dermatitis
Dr. Lawrence Eichenfield discusses the meaning of "early intervention" and its potential implications in atopic dermatitis.
The Benefits of Early Intervention in AD: More Than Skin Deep
Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
Navigating Complex Definitions: Early Intervention and Disease Modification in Atopic Dermatitis
Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.
Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller reviews the increased risk of atopic and nonatopic comorbidities associated with atopic dermatitis and discusses the potential of early intervention to mitigate their development.
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD
Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.
Time to Act: Reducing the Impact of Uncontrolled Disease Through Early Intervention
Dr Jason Hawkes describes the importance of early intervention for patients with uncontrolled skin diseases and the effectiveness of evidence-based management strategies, sharing a patient case and his clinical insights with chronic spontaneous urticaria. Drs Eichenfield, Elmariah, and Culton join to review the burdens faced by patients with atopic dermatitis, prurigo nodularis, and bullous pemphigoid, respectively.
The Potential Sequelae of Missed Opportunities: How Systemic Type 2 Inflammation Can Shape a Patient's Life
Dr. Nicole Chase describes a potential hypothesis for the link between the shift to an industrialized society and the rise in type 2 inflammatory diseases, highlighting the loss of immunomodulatory mechanisms driven by helminthic infections. She explains how unopposed immune responses to common environmental allergens may cause chronic type 2 inflammation, manifesting throughout the body.
Breaking the Cycle of AD in Adults: Minimizing Cumulative Burden Beyond Skin and Achieving Sustained Disease Control
Prof. Tilo Biedermann discusses the key roles of type 2 cytokines IL-4, IL-13, and IL-31 in the pathophysiology of atopic dermatitis. He then describes how these cytokines can be targeted with systemic therapies to elicit long-term disease control and reduce the burden of atopic and non-atopic comorbidities, which are meaningful outcomes for patients with uncontrolled disease.
Beyond Signs and Symptoms: Broadening Treatment Goals in Dermatology
Dr Lawrence Eichenfield explores the broadening of treatment goals for long-term disease control, highlighting the importance of this approach in atopic dermatitis. Drs Culton, Elmariah, and Hawkes expand the discussion to further examine specific management goals unique to each skin disease (bullous pemphigoid, prurigo nodularis, and chronic spontaneous urticaria).
